Toxicity and Costs of Toxicity Associated With New Cancer Drugs: International Implications
A partir d'une revue systématique de la littérature (41 études, 27 539 patients, 19 médicaments expérimentaux), cette méta-analyse évalue les coûts associés à la prise en charge des toxicités des nouveaux médicaments anticancéreux
New cancer drugs provide hope for millions of individuals worldwide. These opportunities, often accompanied by expensive price tags, require discussions of the true clinical value of these agents. Although Amir et al. previously described the benefits and market costs of these new cancer agents, the current study by Nirula et al. addresses equally important but different questions. What are the adverse effects of new anticancer drugs? Are more targeted drugs distinctly different from other cancer therapies with respect to toxicities? What is the financial burden associated with these toxicities? These therapies bring new therapeutic possibilities. However, high expectations can be easily dampened by the occurrence of serious, frequent, or costly toxicities. As the authors opine, it is important to knowin advance whether allocating resources tonewanticancer drugs is reasonable in relation to other priorities and whether allocation of resources is efficient and appropriate......
Journal of Clinical Oncology , éditorial en libre accès, 2014